Trial Outcomes & Findings for Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2 (NCT NCT02777593)

Last Updated: 2025-02-12

Results Overview

Primary Endpoint was composite of the following events: device technical success and absence of aortic rupture, lesion-related mortality, disabling stroke, permanent paraplegia, permanent paraparesis, new onset renal failure requiring permanent dialysis, additional unanticipated post-procedural surgical or interventional procedure related to the device/procedure/withdrawal of the delivery system. Limited to 30 days: disabling stroke, permanent paraplegia, permanent paraparesis, new onset renal failure requiring permanent dialysis.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

Target enrollment

250 participants

Primary outcome timeframe

12 Months

Results posted on

2025-02-12

Participant Flow

Participant milestones

Participant milestones
Measure	Zone 2 Aneurysm Cohort Aneurysm arm, hypothesis-driven cohort	Zone 2 Dissection Cohort Non-aneurysm arm, dissection cohort	Zone 2 Traumatic Transection Cohort Non-aneurysm arm, traumatic transection cohort	Zone 2 Other Isolated Lesion Cohort Non-aneurysm arm, other isolated lesion cohort	Zone 2 Aneurysm Continued Access Aneurysm arm, continued access subjects
Overall Study STARTED	85	136	10	13	6
Overall Study COMPLETED	44	54	1	1	0
Overall Study NOT COMPLETED	41	82	9	12	6

Reasons for withdrawal

Reasons for withdrawal
Measure	Zone 2 Aneurysm Cohort Aneurysm arm, hypothesis-driven cohort	Zone 2 Dissection Cohort Non-aneurysm arm, dissection cohort	Zone 2 Traumatic Transection Cohort Non-aneurysm arm, traumatic transection cohort	Zone 2 Other Isolated Lesion Cohort Non-aneurysm arm, other isolated lesion cohort	Zone 2 Aneurysm Continued Access Aneurysm arm, continued access subjects
Overall Study Still in study	1	32	3	6	5
Overall Study Death	21	28	0	5	0
Overall Study Withdrawal by Subject	8	4	1	1	0
Overall Study Lost to Follow-up	8	16	5	0	1
Overall Study Physician Decision	2	2	0	0	0
Overall Study Discontinued due to Other	1	0	0	0	0

Baseline Characteristics

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Zone 2 Aneurysm Cohort n=84 Participants Aneurysm arm, hypothesis-driven cohort	Zone 2 Dissection Cohort n=136 Participants Non-aneurysm arm, dissection cohort	Zone 2 Traumatic Transection Cohort n=9 Participants Non-aneurysm arm, traumatic transection cohort	Zone 2 Other Isolated Lesion Cohort n=13 Participants Non-aneurysm arm, other isolated lesion cohort	Zone 2 Aneurysm Continued Access n=6 Participants Aneurysm arm, continued access subjects	Total n=248 Participants Total of all reporting groups
Age, Continuous	70.3 years STANDARD_DEVIATION 11.1 • n=5 Participants	62.7 years STANDARD_DEVIATION 11.2 • n=7 Participants	42.4 years STANDARD_DEVIATION 19.0 • n=5 Participants	64.8 years STANDARD_DEVIATION 13.3 • n=4 Participants	59.8 years STANDARD_DEVIATION 15.9 • n=21 Participants	64.5 years STANDARD_DEVIATION 12.9 • n=8 Participants
Sex: Female, Male Female	31 Participants n=5 Participants	33 Participants n=7 Participants	1 Participants n=5 Participants	7 Participants n=4 Participants	3 Participants n=21 Participants	75 Participants n=8 Participants
Sex: Female, Male Male	53 Participants n=5 Participants	103 Participants n=7 Participants	8 Participants n=5 Participants	6 Participants n=4 Participants	3 Participants n=21 Participants	173 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=5 Participants	7 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	0 Participants n=21 Participants	16 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	82 Participants n=5 Participants	127 Participants n=7 Participants	5 Participants n=5 Participants	10 Participants n=4 Participants	6 Participants n=21 Participants	230 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants
Race/Ethnicity, Customized White	67 Participants n=5 Participants	99 Participants n=7 Participants	5 Participants n=5 Participants	9 Participants n=4 Participants	5 Participants n=21 Participants	185 Participants n=8 Participants
Race/Ethnicity, Customized Black or African American	12 Participants n=5 Participants	29 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	44 Participants n=8 Participants
Race/Ethnicity, Customized Asian	3 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	6 Participants n=8 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized Hawaiian or Pacific Islander	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants
Race/Ethnicity, Customized Other	1 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	10 Participants n=8 Participants
Race/Ethnicity, Customized Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
BMI	28.8 kg/(m^2) STANDARD_DEVIATION 6.3 • n=5 Participants	30.6 kg/(m^2) STANDARD_DEVIATION 6.5 • n=7 Participants	29.5 kg/(m^2) STANDARD_DEVIATION 5.0 • n=5 Participants	25.8 kg/(m^2) STANDARD_DEVIATION 5.3 • n=4 Participants	36.3 kg/(m^2) STANDARD_DEVIATION 8.3 • n=21 Participants	29.8 kg/(m^2) STANDARD_DEVIATION 6.5 • n=8 Participants

PRIMARY outcome

Timeframe: 12 Months

Population: Two participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection) that are counted in the Participant Flow section above are excluded from this analysis, as pre-specified, due to a major I/E violation or an FDA-mandated exclusion. Primary Endpoint composite denominator was restricted to number of participants either with a primary endpoint event or imaging performed in the 12 Month window.

Outcome measures

Outcome measures
Measure	Zone 2 Aneurysm Cohort n=74 Participants Aneurysm arm, hypothesis-driven cohort	Zone 2 Dissection Cohort n=109 Participants Non-aneurysm arm, dissection cohort	Zone 2 Traumatic Transection Cohort n=6 Participants Non-aneurysm arm, traumatic transection cohort	Zone 2 Other Isolated Lesion Cohort n=8 Participants Non-aneurysm arm, other isolated lesion cohort	Zone 2 Aneurysm Continued Access n=6 Participants Aneurysm arm, continued access subjects
Proportion of Participants With Primary Endpoint Success for Zone 2	0.838 proportion of participants	0.881 proportion of participants	1.0 proportion of participants	0.875 proportion of participants	1.0 proportion of participants

Adverse Events

Zone 2 Aneurysm Cohort

Serious events: 61 serious events

Other events: 74 other events

Deaths: 21 deaths

Zone 2 Dissection Cohort

Serious events: 99 serious events

Other events: 111 other events

Deaths: 28 deaths

Zone 2 Traumatic Transection Cohort

Serious events: 3 serious events

Other events: 7 other events

Deaths: 0 deaths

Zone 2 Other Isolated Lesion Cohort

Serious events: 9 serious events

Other events: 11 other events

Deaths: 5 deaths

Zone 2 Aneurysm Continued Access

Serious events: 4 serious events

Other events: 4 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Zone 2 Aneurysm Cohort n=85 participants at risk Aneurysm arm, hypothesis-driven cohort	Zone 2 Dissection Cohort n=136 participants at risk Non-aneurysm arm, dissection cohort	Zone 2 Traumatic Transection Cohort n=10 participants at risk Non-aneurysm arm, traumatic transection cohort	Zone 2 Other Isolated Lesion Cohort n=13 participants at risk Non-aneurysm arm, other isolated lesion cohort	Zone 2 Aneurysm Continued Access n=6 participants at risk Aneurysm arm, continued access subjects
Gastrointestinal disorders Colocutaneous fistula	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Colonic polyp	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Acute anemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Acute blood loss anemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Anemia	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Anemia of chronic disease	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Blood loss anemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Chemotherapy induced neutropenia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Coagulopathy	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Disseminated intravascular coagulation	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Hemolytic anemia drug-induced	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Heparin-induced thrombocytopenia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Leukocytosis	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Neutropenic fever	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Normocytic anemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Symptomatic anemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Vaso-occlusive crisis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Acute heart failure	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Acute myocardial infarction	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Acute myocardial infarction type 2	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Acute on chronic heart failure	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Aortic valve insufficiency	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Aortic valve stenosis	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Arrhythmia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Asystole	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Atrial fibrillation	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Atrial fibrillation aggravated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Atrial fibrillation with rapid ventricular response	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Atrial flutter	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Bradycardia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Cardiac arrest	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.1% 7/136 • Number of events 9 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Cardiac failure aggravated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Cardiac failure chronic aggravated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Cardiac tamponade	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Cardiogenic shock	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Chest pain - cardiac	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Chronic atrial fibrillation	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Chronic diastolic heart failure	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Complete heart block	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Congestive cardiac failure aggravated	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Congestive heart failure	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	4.4% 6/136 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Heart block AV	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Left ventricular systolic dysfunction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Mitral regurgitation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Mobitz (type) II atrioventricular block	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Myocardial infarction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Myocardial ischaemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Non ST segment elevation myocardial infarction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Non-sustained ventricular tachycardia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Paroxysmal atrial fibrillation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Pericardial effusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Persistent atrial fibrillation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Right coronary artery stenosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders ST segment elevation myocardial infarction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Sick sinus syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Tachyarrhythmia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Type II second degree atrioventricular block	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Unstable angina	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Ventricular arrhythmia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Ventricular fibrillation	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Congenital, familial and genetic disorders Gastrointestinal arteriovenous malformation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Congenital, familial and genetic disorders Sickle-cell beta thalassemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Ear and labyrinth disorders Vertigo	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Endocrine disorders Adrenal mass	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Endocrine disorders Primary hyperthyroidism	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Cataract (left)	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Cataracts	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Detached retina	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Epiretinal membrane	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Retinal detachment	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Sudden visual loss	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Vision loss	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Abdominal hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Abdominal pain	3.5% 3/85 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Celiac artery aneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Celiac artery stenosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Constipation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Crohns disease aggravated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Diarrhea	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Diverticulosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Diverticulum of esophagus, acquired	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Dysphagia	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Gastric ulcer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Gastroesophageal reflux disease	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Gastrointestinal bleed	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Gastrointestinal bleeding	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Gastroparesis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Hiatal hernia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Ileus	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Incarcerated umbilical hernia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Inguinal hernia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Ischemic colitis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Large intestine perforation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Left inguinal hernia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Mesenteric artery stenosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Mesenteric ischemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Nausea	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Neurogenic bowel	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Partial small intestinal obstruction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Rectal bleeding	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Retroperitoneal hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Right inguinal hernia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Small bowel obstruction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Upper gastrointestinal bleeding	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Ventral hernia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Vomiting	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Catheter related thrombosis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Chest pain (non-cardiac)	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Continued perfusion of a false lumen	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Debility	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Distal aorta false lumen perfusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Distal branch false lumen perfusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Edema lower limb	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Fever	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Fever of unknown origin	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Multiple organ failure	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Non-cardiac chest pain	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Slight fever	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent thrombosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type IA	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type IB	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type IC	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type II	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type III	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Unilateral leg swelling	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Unknown cause of death	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Unspecified chest pain	1.2% 1/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Vascular stent-graft occlusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Acute cholecystitis	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Bile duct obstruction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Biliary colic	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Chronic cholecystitis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Gallbladder disorder	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Hepatic cyst	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Transaminitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Abscess	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Acute cystitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Acute exacerbation of chronic bronchitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Acute pneumonia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Appendicitis perforated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Aspiration pneumonia	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Bacteremia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations COVID-19	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations COVID-19 pneumonia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Cellulitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Cellulitis of leg	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Cellulitis streptococcal	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Clostridium difficile infection	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Colon diverticulitis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Community acquired pneumonia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Diverticulitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Diverticulitis intestinal	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Endocarditis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Endocarditis infective	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Gangrene	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Graft infection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Groin infection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Haemophilus parainfluenzae infection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Healthcare associated pneumonia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Intra-abdominal abscess	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Klebsiella pneumonia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Klebsiella septicemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Methicillin-resistant Staphylococcus aureus infection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Methicillin-resistant Staphylococcus aureus sepsis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Mitral valve endocarditis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Neutropenic sepsis	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Osteomyelitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Pericolic abscess	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Peritonitis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Pneumonia	7.1% 6/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Pneumonia pseudomonal	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Pulmonary sepsis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Pyelonephritis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Retroperitoneal abscess	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Sepsis	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Septic shock	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Spinal osteomyelitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Staphylococcus aureus bacteremia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Urinary tract infection	4.7% 4/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	4.4% 6/136 • Number of events 9 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Urosepsis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Vascular graft infection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Vascular stent graft infection	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Wound infection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Anastomotic bleeding	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Anemia postoperative	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Aortic pseudoaneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Arteriovenous fistula thrombosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Brain herniation	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Broken leg	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Closed fracture of unspecified part of tibia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Concussion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Device placement at incorrect location	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Fall	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Femoral artery pseudoaneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Femur fracture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Fracture of intertrochanteric section of femur, closed	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Fractured finger	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Fractured hip	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Fractured ribs	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Great toe fracture	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Hemodilution	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Hip fracture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Incision site bleeding	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Intraoperative hemorrhage	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Nephrostomy complication	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Post procedural hematuria	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Post spinal headache	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Postimplantation syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Postoperative ileus	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Postoperative respiratory failure	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Pseudoaneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Rupture spleen	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Subdural hematoma	3.5% 3/85 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Subdural hemorrhage	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Third degree burns	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Vascular access site rupture	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Vascular pseudoaneurysm	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Vertebral fracture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Investigations Red blood cells in cerebrospinal fluid	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Investigations Troponin increased	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Acidosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Failure to thrive	3.5% 3/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Fluid overload	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hypercalcemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hyperglycemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hypernatremia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hypoglycemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hypoglycemia aggravated	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hypokalemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hyponatremia	4.7% 4/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hyponatremia aggravated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hypovolemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Metabolic acidosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Protein-calorie malnutrition	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Type II diabetes mellitus	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Volume overload	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Cervical spinal stenosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Chest wall hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Degenerative joint disease	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Degenerative spondylolisthesis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Interscapular pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Knee arthritis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Low back pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Lower extremities weakness of	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Olecranon bursitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Osteoarthritis knee	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Pain in thigh	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Rotator cuff tear arthropathy	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Shoulder pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Spinal stenosis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Upper back pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ductal carcinoma in situ	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hormone-refractory prostate cancer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm of sigmoid colon	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic cancer	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin cancer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of head and neck	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Vulvar cancer	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Acute migraine	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Acute toxic metabolic encephalopathy	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Anoxic brain damage	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Anoxic encephalopathy	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Anterior spinal artery syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Aphasia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Brain compression	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Carotid artery disease	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Carotid artery dissection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Carotid artery insufficiency	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Carotid artery stenosis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Cerebellar stroke	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Cerebral hemorrhage	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Cerebral ischemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Cerebral small vessel ischemic disease	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Cerebrovascular accident	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Convulsive status epilepticus	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Dizziness	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Embolic stroke	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Encephalopathy	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Encephalopathy acute	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Headache	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Hemorrhagic stroke	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Hydrocephalus	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Intracerebral hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Intracerebral hemorrhage	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Intraparenchymal cerebral hemorrhage	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Intraventricular hemorrhage	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Ischemic stroke	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Metabolic encephalopathy	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Near syncope	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Neuropathy peripheral	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Nonconvulsive status epilepticus	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Numbness in hand	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Paralysis leg	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Paraplegia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Seizure	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Spinal cord infarction	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Spinal cord ischemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Stroke	3.5% 3/85 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Stroke syndrome	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Stupor	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Subarachnoid hemorrhage	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Syncopal attack	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Syncope	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Tonic-clonic seizures	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Transient global amnesia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Transient ischemic attack	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Vocal cord paralysis	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Product Issues Device dislodgement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Product Issues Device lead fracture	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Alcohol withdrawal syndrome	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Confusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Conversion disorder	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Delirium	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Intensive care unit delirium	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Mental status changes	2.4% 2/85 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Acute kidney injury	9.4% 8/85 • Number of events 8 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	4.4% 6/136 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Acute renal failure	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Acute renal insufficiency	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Acute tubular necrosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Chronic kidney disease stage 3	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Kidney atrophic	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Kidney stones	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Nephrolithiasis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Nephropathy	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Nephrotic syndrome	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Neurogenic bladder	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal artery stenosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal calculi	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal failure	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal failure aggravated	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal mass	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Stone urinary bladder	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Ureter obstruction	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Ureteral calculus	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Urethral stricture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Urinary retention	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Reproductive system and breast disorders Benign prostatic hyperplasia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Reproductive system and breast disorders Benign prostatic hypertrophy	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Reproductive system and breast disorders Pelvic floor dysfunction	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Reproductive system and breast disorders Rectocele	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Reproductive system and breast disorders Uterovaginal prolapse	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Reproductive system and breast disorders Vaginal bleeding	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Acute hypoxic respiratory failure	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Acute pulmonary edema	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Acute respiratory insufficiency	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Chronic respiratory failure	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Deviated nasal septum	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Dyspnea	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Dyspnea exacerbated	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Epistaxis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Flash pulmonary edema	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hemoptysis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hemothorax	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hypercapnic respiratory failure	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hypercarbia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hypoxemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hypoxia	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Hypoxic respiratory failure	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pleural effusion	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pneumothorax	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pulmonary edema	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Respiratory failure	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Respiratory insufficiency	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Shortness of breath	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Skin and subcutaneous tissue disorders Decubitus	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Skin and subcutaneous tissue disorders Ecchymosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Skin and subcutaneous tissue disorders Pressure ulcer	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Abdominal aortic aneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Abdominal aortic aneurysm enlargement	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Accelerated hypertension	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Acute hemorrhage	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Acute limb ischemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aneurysm enlargement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic aneurysm	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic aneurysm enlargement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic aneurysm rupture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic dissection	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic dissection rupture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic intramural hematoma	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Aortic rupture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Arterial hemorrhage	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Arterial rupture	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Arteriovenous fistula	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Ascending aortic dissection	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Atherosclerotic cardiovascular disease	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Deep vein thrombosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Deep vein thrombosis leg	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Deep venous thrombosis arm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Dissecting aortic aneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Embolism limb	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Femoral artery dissection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Groin haematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Groin hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hematoma	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hemodynamic instability	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hemorrhagic shock	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypertension	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	15.4% 2/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypertension worsened	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypertensive crisis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypertensive emergency	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypertensive urgency	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypotension	4.7% 4/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Iliac artery aneurysm enlargement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Iliac artery dissection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Iliac artery occlusion	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Iliac artery rupture	3.5% 3/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Iliofemoral artery thrombosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Inferior vena cava stenosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Orthostatic hypotension	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Peripheral artery dissection	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Popliteal artery aneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Retrograde aortic dissection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Shock, unspecified	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Subclavian artery stenosis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Subclavian steal syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Thoracic aortic aneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Thoracic aortic aneurysm enlargement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Thoracoabdominal aortic aneurysm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Thoracoabdominal aortic aneurysm enlargement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Thromboembolism	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Type A aortic dissection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Type B aortic dissection	1.2% 1/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Uncontrolled hypertension	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Venous stasis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure

Other adverse events

Other adverse events
Measure	Zone 2 Aneurysm Cohort n=85 participants at risk Aneurysm arm, hypothesis-driven cohort	Zone 2 Dissection Cohort n=136 participants at risk Non-aneurysm arm, dissection cohort	Zone 2 Traumatic Transection Cohort n=10 participants at risk Non-aneurysm arm, traumatic transection cohort	Zone 2 Other Isolated Lesion Cohort n=13 participants at risk Non-aneurysm arm, other isolated lesion cohort	Zone 2 Aneurysm Continued Access n=6 participants at risk Aneurysm arm, continued access subjects
Blood and lymphatic system disorders Anemia	5.9% 5/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.1% 7/136 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Blood loss anemia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Hypercoagulability	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Hypercoagulation	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Blood and lymphatic system disorders Leukocytosis	5.9% 5/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Atrial fibrillation	8.2% 7/85 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	4.4% 6/136 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Long QT syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Non ST segment elevation myocardial infarction	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Tachycardia	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	20.0% 2/10 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Cardiac disorders Tricuspid regurgitation	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Blurry vision	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Eye disorders Diplopia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Abdominal pain	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	23.1% 3/13 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Acid reflux (esophageal)	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Constipation	4.7% 4/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Epigastric pain	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Gastrointestinal bleed	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Hiatal hernia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Mesenteric edema	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Retroperitoneal hematoma	5.9% 5/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Stomach pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Superior mesenteric artery syndrome	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Gastrointestinal disorders Upper abdominal pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Arterial stent occlusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Edema of lower extremities	5.9% 5/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Fever	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	6.6% 9/136 • Number of events 9 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Low grade fever	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Non-cardiac chest pain	10.6% 9/85 • Number of events 10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.9% 8/136 • Number of events 10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	20.0% 2/10 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	38.5% 5/13 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type IA	7.1% 6/85 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Stent-graft endoleak type II	11.8% 10/85 • Number of events 11 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Substernal pain	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Unilateral leg swelling	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Vascular stent-graft thrombosis	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
General disorders Weakness generalized	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Hepatobiliary disorders Cholecystitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Acute bronchitis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations COVID-19	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.1% 7/136 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Cellulitis of leg	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Influenza	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Pneumonia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Upper respiratory infection	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Infections and infestations Urinary tract infection	5.9% 5/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.1% 7/136 • Number of events 8 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Fall	8.2% 7/85 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Incision site hematoma	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Incision site pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Postoperative pain	5.9% 5/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Tick bite	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Injury, poisoning and procedural complications Wrist injury	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Investigations Weight loss	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Appetite lost	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Hyperkalemia	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Metabolism and nutrition disorders Volume overload	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Back pain	4.7% 4/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.9% 8/136 • Number of events 8 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Lower extremities weakness of	3.5% 3/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Lumbar pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Musculoskeletal and connective tissue disorders Neck pain	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Dementia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Encephalopathy acute	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Headache	7.1% 6/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Neuralgia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Numbness in feet	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Numbness in fingers	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Numbness in leg	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Numbness of upper arm	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Numbness of upper extremities	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Paresthesia lower limb	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Presyncope	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Nervous system disorders Tingling of extremity	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Pregnancy, puerperium and perinatal conditions Pre-eclampsia	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Anxiety	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	15.4% 2/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Anxiety disorder	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Delirium	5.9% 5/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Psychiatric disorders Major depression	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Acute kidney injury	3.5% 3/85 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	15.4% 2/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Acute tubular necrosis	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Chronic kidney disease stage 3	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Hematuria	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Oliguria	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Renal infarction	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Ureteral calculus	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Renal and urinary disorders Urinary retention	7.1% 6/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	15.4% 2/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Atelectasis	5.9% 5/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Bilateral pleural effusion	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease exacerbation	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Cough	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.2% 3/136 • Number of events 3 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Epistaxis	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Exercise dyspnea	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Lung nodule	2.4% 2/85 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	4.4% 6/136 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pleural effusion	1.2% 1/85 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.9% 8/136 • Number of events 8 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Pulmonary collapse	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Respiratory, thoracic and mediastinal disorders Shortness of breath	5.9% 5/85 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	5.1% 7/136 • Number of events 7 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Artery dissection	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.74% 1/136 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Ascending aortic aneurysm enlargement	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	16.7% 1/6 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypertension	5.9% 5/85 • Number of events 6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	3.7% 5/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	15.4% 2/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypotension	7.1% 6/85 • Number of events 8 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	2.9% 4/136 • Number of events 5 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Hypotension symptomatic	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Iliac artery dissection	4.7% 4/85 • Number of events 4 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	1.5% 2/136 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	15.4% 2/13 • Number of events 2 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Penetrating atherosclerotic ulcer	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/10 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	7.7% 1/13 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure
Vascular disorders Subclavian artery occlusion	0.00% 0/85 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/136 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	10.0% 1/10 • Number of events 1 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/13 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure	0.00% 0/6 • Adverse events collected for 60 Months, rates shown are through all reported follow-up, follow-up is ongoing for participants who have not completed the study. The two excluded participants (1 Zone 2 Aneurysm and 1 Zone 2 Traumatic Transection due to a major I/E violation or an FDA-mandated exclusion) have been included in this Adverse Events section. Collection starting at endovascular procedure

Additional Information

Meier Hsu

W.L. Gore

Phone: 928-864-3338

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place